Home
HelpTest Code GFATS Glial Fibrillary Acidic Protein Alpha Subunit Antibody, Immunofluorescence Titer Assay, Serum
Necessary Information
Provide the following information:
-Relevant clinical information
-Ordering provider name, phone number, mailing address, and e-mail address
Specimen Required
Only orderable as a reflex. For more information see:
ENS2 / Encephalopathy, Autoimmune Evaluation Serum
DMS2 / Dementia, Autoimmune Evaluation, Serum
EPS2 / Epilepsy, Autoimmune Evaluation, Serum
MAS1 / Autoimmune Myelopathy Evaluation, Serum
Useful For
Reporting an end titer result in serum specimens
Distinguishing autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy from infectious meningoencephalitis and idiopathic inflammatory central nervous system (CNS) disorders such as multiple sclerosis, vasculitis and sarcoidosis, disorders commonly considered in the differential diagnosis
Alerting the clinician that the patient has an immune-mediated, steroid-responsive disorder and to search for a malignancy
Testing Algorithm
If immunofluorescence assay (IFA) pattern suggests GFAP, then GFAP IFA titer and GFAP cell-binding assay (CBA) are performed at an additional charge.
Method Name
Only orderable as a reflex. For more information see:
ENS2 / Encephalopathy, Autoimmune Evaluation Serum
DMS2 / Dementia, Autoimmune Evaluation, Serum
EPS2 / Epilepsy, Autoimmune Evaluation, Serum
MAS1 / Autoimmune Myelopathy Evaluation, Serum
Indirect Immunofluorescence Assay (IFA)
Reporting Name
GFAP IFA Titer, SSpecimen Type
SerumSpecimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 28 days | |
| Frozen | 28 days | ||
| Ambient | 72 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Clinical Information
Antibody targeting glial fibrillary acidic protein (GFAP)-IgG is a biomarker of a subacute and progressive autoimmune meningitis, encephalitis, and myelitis that can mimic multiple sclerosis (MS) or other idiopathic inflammatory central nervous system (CNS) disorders such as sarcoidosis. Neurological manifestations include headache, optic neuropathy, transverse myelitis, cognitive decline, and cerebellar ataxia. Cerebrospinal fluid (CSF) is inflammatory. Cranial magnetic resonance (MR) imaging reveals linear perivascular enhancement oriented radially to ventricles. A paraneoplastic neurological context is common. Reported neoplasms accompanying neurological symptoms include adenocarcinomas (prostate and gastroesophageal), myeloma, melanoma, colonic carcinoid, parotid pleomorphic adenoma, and teratoma. If GFAP-IgG is detected by immunofluorescence assay (IFA), it is reflexed to a test for the alpha isoform of GFAP (GFAPalpha-IgG) by cell based assay.
Reference Values
Only orderable as a reflex. For more information see:
ENS2 / Encephalopathy, Autoimmune Evaluation Serum
DMS2 / Dementia, Autoimmune Evaluation, Serum
EPS2 / Epilepsy, Autoimmune Evaluation, Serum
MAS1 / Autoimmune Myelopathy Evaluation, Serum
<1:240
Interpretation
Seropositivity for autoantibody (positive) is supportive of autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy, a treatable form of meningoencephalomyelitis. A paraneoplastic basis should be considered, according to age, sex, and other risk factors.
Patients who are GFAP-IgG positive have increased risk of tumor. GFAP-IgG increases the likelihood of certain malignancies being found within 2 years of symptom onset (34%). The most common malignancy found is ovarian teratoma (22%).
GFAP meningoencephalomyelitis is immunotherapy-responsive. GFAP-IgG positive patients have better outcomes after treatment with corticosteroids.
The presence of GFAP-IgG alerts the clinician that the patient has an immune-mediated, steroid-responsive disorder and directs patient care accordingly. It also alerts the clinician to search for a malignancy.
Cautions
Negative results do not exclude the diagnosis of autoimmune meningoencephalomyelitis or cancer.
Method Description
The patient's sample is tested by a standardized indirect immunofluorescence assay (IFA) that uses a composite frozen section of mouse cerebellum, kidney, and gut tissues. After incubation with sample and washing, fluorescein-conjugated goat antihuman IgG is applied. Neuron-specific autoantibodies are identified by their characteristic fluorescence staining patterns. Samples that are scored positive for any neuronal nuclear or cytoplasmic autoantibody are titrated to an endpoint. Interference by coexisting non-neuron-specific autoantibodies can usually be eliminated by serologic absorption.(Yu Z, Kryzer TJ, Griesmann GE, et al: CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146-154)
Day(s) Performed
Monday through Sunday
Report Available
10 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86256
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| GFATS | GFAP IFA Titer, S | 93423-2 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 605133 | GFAP IFA Titer, S | 93423-2 |